Sharp Therapeutics (Biotechnology) Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
SHRX
- Share Price
-
$0.98
- (As of Monday Closing)
Sharp Therapeutics (Biotechnology) General Information
Description
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
Contact Information
Website
www.sharptx.comCorporate Office
- 2403 Sidney Street
- Suite 264
- Pittsburgh, PA 15203
- United States
Corporate Office
- 2403 Sidney Street
- Suite 264
- Pittsburgh, PA 15203
- United States
Sharp Therapeutics (Biotechnology) Timeline
Sharp Therapeutics (Biotechnology) Stock Performance
As of 21-Sep-2026, Sharp Therapeutics (Biotechnology)’s stock price is $0.98. Its current market cap is $30.9M with 31.6M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.98 | $0.99 | $0.16 - $3.55 | $30.9M | 31.6M | 1.4K | -$0.17 |
Sharp Therapeutics (Biotechnology) Financials Summary
As of 30-Jun-2026, Sharp Therapeutics (Biotechnology) has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 19,572 | 54,184 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (4,924) | (5,909) | (2,989) | (3,276) |
| Net Income | (5,181) | (6,174) | (3,261) | (3,565) |
| Total Assets | 1,042 | 1,952 | 4,554 | 1,546 |
| Total Debt | 2,258 | 1,283 | 1,316 | 8,419 |
Sharp Therapeutics (Biotechnology) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sharp Therapeutics (Biotechnology) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sharp Therapeutics (Biotechnology) Comparisons
Industry
Financing
Details
Sharp Therapeutics (Biotechnology) Competitors (49)
One of Sharp Therapeutics (Biotechnology)’s 49 competitors is Adimab, a Venture Capital-Backed company based in Lebanon, NH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
Sharp Therapeutics (Biotechnology) Signals
Sharp Therapeutics (Biotechnology) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sharp Therapeutics (Biotechnology) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Diversified Financials
Industry
Rank
Percentile
Asset Management and Custody Services
Subindustry
Rank
Percentile
Sharp Therapeutics (Biotechnology) FAQs
-
When was Sharp Therapeutics (Biotechnology) founded?
Sharp Therapeutics (Biotechnology) was founded in 2010.
-
Where is Sharp Therapeutics (Biotechnology) headquartered?
Sharp Therapeutics (Biotechnology) is headquartered in Pittsburgh, PA.
-
What is the size of Sharp Therapeutics (Biotechnology)?
Sharp Therapeutics (Biotechnology) has 5 total employees.
-
What industry is Sharp Therapeutics (Biotechnology) in?
Sharp Therapeutics (Biotechnology)’s primary industry is Biotechnology.
-
Is Sharp Therapeutics (Biotechnology) a private or public company?
Sharp Therapeutics (Biotechnology) is a Public company.
-
What is Sharp Therapeutics (Biotechnology)’s stock symbol?
The ticker symbol for Sharp Therapeutics (Biotechnology) is SHRX.
-
What is the current stock price of Sharp Therapeutics (Biotechnology)?
As of 21-Sep-2026 the stock price of Sharp Therapeutics (Biotechnology) is $0.98.
-
What is the current market cap of Sharp Therapeutics (Biotechnology)?
The current market capitalization of Sharp Therapeutics (Biotechnology) is $30.9M.
-
Who are Sharp Therapeutics (Biotechnology)’s competitors?
Adimab, CRISPR Therapeutics, Immunocore Holdings, Adaptimmune Therapeutics, and Intellia Therapeutics are some of the 49 competitors of Sharp Therapeutics (Biotechnology).
-
What is Sharp Therapeutics (Biotechnology)’s annual earnings per share (EPS)?
Sharp Therapeutics (Biotechnology)’s EPS for 12 months was -$0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process